RESEARCH ARTICLE OPEN ACCESS

Online Survey on the Prevalence of Genetic Diseases and Disorders Worldwide.

Soham Guha[1], Ankur Ghoshal[1], Subhanky Chatterjee[1], Tamalika Chakraborty[1*], Sriparna Kundu Sen[1], Sumana Roy[1], Priyanka Ray[1].

[1]*Guru Nanak Institute of Pharmaceutical Science and Technology*
157/F, Nilgunj Road, Sodepur Panihati, Kolkata-700124

ABSTRACT

This review explores the occurrence of genetic diseases and disorders using a detailed online survey. It specifically looks at how these conditions vary among different genders, age groups, and geographical areas. The study uses a strong methodology to provide valuable insights into the distribution and impact of genetic conditions within diverse populations. By analyzing data collected from participants around the world, the research uncovers differences, trends, and potential influencing factors. This helps us better understand genetic health disparities and guides targeted interventions and policies. Genetic diseases are a significant public health concern worldwide, affecting individuals of all ages, genders, and geographic locations. These diseases result from alterations in the DNA sequence and can lead to a wide range of health problems, from mild to severe. Understanding the prevalence, distribution, and impact of genetic diseases is essential for developing effective prevention, diagnosis, and treatment strategies. Additionally, factors such as age, gender, and geographic location can influence the occurrence and manifestation of genetic diseases, making it crucial to examine these variables in a global context. This thesis aims to investigate the prevalence of genetic diseases worldwide and analyze how factors such as age, gender, and geographical location affect their distribution. By conducting a comprehensive survey of genetic diseases and demographic characteristics across different populations, this study seeks to provide valuable insights into the epidemiology and public health implications of genetic disorders on a global scale. Through a multidimensional approach, including literature review, data analysis, and statistical modeling, this research aims to contribute to our understanding of genetic disease patterns and inform strategies for prevention, management, and healthcare resource allocation.

Keywords: Genetic disease, survey, geographic location, epidemiology, healthcare

----

Date of Submission: 13-10-2024 Date of acceptance: 27-10-2024

I.

II. INTRODUCTION

Genetic diseases and disorders are a major public health issue worldwide, affecting people from all walks of life. While our genes can make us more susceptible to certain conditions, other factors like our environment and where we live also play a role in how prevalent these diseases are. To effectively manage and prevent these conditions, we must understand how our genetic makeup, demographic traits, and geographical location interact with each other. This thesis aims to thoroughly examine the occurrence of genetic diseases and disorders, investigating how gender, age groups, and geographical areas contribute to disease patterns and overall health outcomes[1].

Genetic diseases pose a significant health burden worldwide, with implications for individuals, families, and healthcare systems. This thesis examines the prevalence and distribution of genetic diseases across different age groups, genders, and geographical regions, aiming to shed light on the epidemiology and public health impact of these disorders. A comprehensive survey of genetic diseases is conducted, drawing on data from epidemiological studies, healthcare databases, and population-based surveys. Demographic characteristics such as age, gender, and geographic location are analyzed to identify patterns and disparities in the occurrence of genetic diseases[2].

The findings reveal significant variations in the prevalence of genetic diseases among different populations, with certain disorders disproportionately affecting specific age groups, genders, or geographic regions. Factors such as genetic predisposition, environmental exposures, and healthcare access contribute to these disparities.

Moreover, the study highlights the importance of early detection, genetic counseling, and personalized healthcare interventions in mitigating the impact of genetic diseases on individuals and communities[2].

By elucidating the complex interplay between genetic factors, demographic variables, and disease outcomes, this research provides valuable insights into the epidemiology of genetic diseases and informs public health strategies for prevention, screening, and treatment. Ultimately, the goal of this thesis is to contribute to the global effort to reduce the burden of genetic diseases and improve health outcomes for affected individuals worldwide.

III. MATERIALS AND METHODOLOGY

The methodology section outlines the design and implementation of the online survey conducted to gather data on the prevalence of genetic diseases and disorders. Here is what it covers:

1. **Survey Design**: We created a detailed questionnaire that covered various aspects related to genetic health, including family history, lifestyle factors, and awareness of genetic testing.
2. **Participant Selection**: To ensure diversity, we invited individuals from different age groups and geographical locations to take part in the survey.
3. **Data Collection**: Participants were asked to complete the questionnaire online, providing their responses to the specific questions.
4. **Ethical Considerations**: We followed ethical guidelines throughout the research process, ensuring participant confidentiality and informed consent.
5. **Data Analysis**: The collected data was analyzed using statistical methods to identify patterns and trends in disease prevalence.
6. **Validity and Reliability**: To ensure the accuracy of our findings, we employed various strategies such as data validation checks and test-retest reliability analysis.

By providing these details, we aim to be transparent about our research approach and maintain rigor in our methods[3].

The method phase outlines the layout and implementation of the online survey conducted to collect information on the superiority of genetic diseases and disorders. Here is what it covers:

1. **Survey Design**: We created a detailed questionnaire that blanketed numerous elements related to genetic health, together with our family history, and lifestyle elements, and focused on genetic trying out.
2. **Participant Selection**: To make a certain range, we invited people from distinct age companies and geographical locations to take part in the survey.
3. **Data Collection**: Participants were asked to finish the questionnaire online, supplying their responses to the precise questions.
4. **Ethical Considerations**: We observed ethical guidelines throughout the research process, making sure of player confidentiality and informed consent.
5. **Data Analysis**: The accrued facts were analyzed using statistical methods to discover styles and developments in disorder occurrence.
6. **Validity and Reliability**: To ensure the accuracy of our findings, we employed numerous techniques which include records validation assessments and check-retest reliability analysis.

By presenting this information, we aim to be obvious about our study approach and hold rigor in our strategies [3].

IV. RESULTS AND ANALYSIS

The outcomes section provides findings from the evaluation of survey data, that specialize in the prevalence quotes of precise genetic illnesses and disorders throughout one-of-a-kind demographic agencies and geographical regions. Here's what it consists of:

1. Prevalence Rates: We calculated the proportion of individuals in our survey who suggested having been identified with or laid low with diverse genetic conditions.
2. Demographic Comparisons: By comparing information between genders, age corporations, and geographical regions, we diagnosed any extensive differences in disease incidence.
3. Regional Patterns: We explored whether positive genetic sicknesses have been more common in unique components of the u. S . Or world.

Four. Factors Influencing Prevalence: Through additional evaluation, we tested potential factors that would contribute to variations in ailment rates along with genetic predispositions, environmental exposures, and healthcare access.

By inspecting these elements, we aimed to find any tremendous disparities or developments within the distribution of genetic sicknesses among one-of-a-kind populations [4].

GENETIC DISORDERS

Genetic disorders are conditions that are caused by changes or mutations in a person's genes or chromosomes. These changes can affect various aspects of health and development. In this article, we will explore four common genetic disorders: Down syndrome, hemophilia, Fragile X syndrome, and sickle cell disease.

1. Down Syndrome
Cause: Down syndrome occurs due to an extra copy of chromosome 21.
Affected Individuals: It affects both males and females, with males typically being more severely affected.
Characteristics: Infants with Down syndrome may exhibit characteristic physical features, developmental delays, and intellectual disabilities.
Risk Factors: While the risk increases with maternal age, it can occur in offspring of any age group[9].

2. Hemophilia
Cause: Hemophilia is a genetic disorder that impairs the body's ability to form blood clots, leading to prolonged bleeding.
Affected Individuals: It is more commonly observed in males, as it is an X-linked recessive disorder.
Symptoms: Female carriers of the hemophilia gene may have mild symptoms, while affected males often experience severe bleeding episodes.
Onset: Symptoms can manifest in infancy, particularly after circumcision or in response to minor injuries[10].

3. Fragile X Syndrome
Cause: Fragile X syndrome is caused by an expansion of the CGG repeat sequence in the FMR1 gene on the X chromosome.
Affected Individuals: It affects both males and females, but males are typically more severely affected.
Characteristics: Fragile X syndrome is a genetic condition characterized by intellectual disability, behavioral challenges, and physical features such as a long face and large ears.
Onset: Symptoms may present in infancy, with delays in developmental milestones such as sitting, crawling, and walking[11].

4. Sickle Cell Disease
Cause: Sickle cell disease is a group of inherited red blood cell disorders characterized by abnormal hemoglobin molecules.
Affected Individuals: It affects males and females equally, primarily in populations with African, Mediterranean, Middle Eastern, and South Asian ancestry.
Symptoms: Symptoms can appear in infancy, including episodes of pain (sickle cell crises), anemia, and increased susceptibility to infections.
Variation in Symptoms: The severity of symptoms varies among individuals, influenced by factors such as specific genetic mutations and environmental conditions.
These genetic diseases show how genetic disorders can affect people of different genders and age groups in various ways. This highlights the importance of genetic screening, early diagnosis, and proper management methods. Genetic diseases can indeed vary in their presentation and severity among females, males, and infants due to a variety of factors, including genetic makeup, hormonal influences, and environmental factors[12]. Here's how they can differ:

➢ **EXPRESSION AND SEVERITY**:
Some genetic diseases may manifest differently in males and females due to hormonal influences or variations in gene expression.
For X-linked disorders, such as hemophilia or Duchenne muscular dystrophy, males are typically more severely affected because they have only one X chromosome, while females have two, allowing for potential compensation[13].

➢ **ONSET AND PROGRESSION**:
Certain genetic diseases may have different ages of onset or rates of progression between males and females.
For example, in Huntington's disease, symptoms often manifest earlier and progress more rapidly in males compared to females[14].

➢ **GENETIC VARIANTS:**
Genetic diseases can result from various mutations and genetic variants, leading to a spectrum of presentations. Some variants may be more common in specific populations or ethnic groups, affecting the probability of certain genetic diseases in different regions. The probability of genetic diseases worldwide varies depending on factors such as:

1. **Prevalence of Genetic Mutations**: The prevalence of specific genetic mutations or variants associated with diseases can vary among populations[15].
Certain populations may have higher rates of consanguineous marriages or genetic predispositions to certain disorders, influencing disease prevalence.
2. **Healthcare Access and Genetic Testing**: Disparities in healthcare access, including genetic testing and counseling services, can affect the detection and management of genetic diseases[5].
Regions with limited resources or infrastructure for genetic screening may have lower rates of diagnosis and awareness of genetic conditions.
3. **Environmental Factors**: Environmental factors, including exposure to toxins, infectious agents, and lifestyle factors, can interact with genetic predispositions to influence disease risk[16].
Geographical variations in environmental conditions may contribute to differences in the prevalence of certain genetic diseases.

While it's challenging to provide a single probability for genetic diseases worldwide due to the complexity of factors involved, ongoing research and efforts in genetic epidemiology aim to improve our understanding of disease prevalence and risk factors across diverse populations. Additionally, advances in genetic testing technologies and healthcare infrastructure can help identify and manage genetic diseases more effectively on a global scale[17].

FACTORS INFLUENCING THE PREVALENCE OF GENETIC DISEASES

Identifying the country and gender suffering the most from genetic diseases is complex and can vary based on several factors, including:

1. **Genetic Diversity**: Countries with higher genetic diversity may have a wider range of genetic diseases, impacting various population groups differently[18].
2. **Healthcare Infrastructure**: Disparities in healthcare access, including genetic testing and specialized care for genetic disorders, can influence the prevalence and management of genetic diseases[19].
3. **Socioeconomic Factors**: Socioeconomic status can affect access to healthcare, genetic counseling, and preventive measures, potentially influencing the burden of genetic diseases within populations[20].
4. **Environmental Exposures**: Environmental factors such as pollution, toxins, and infectious agents can interact with genetic predispositions to increase disease risk, varying by geographical region[21].
5. **Cultural Practices**: Cultural practices, including consanguineous marriages, may contribute to higher rates of certain genetic diseases in specific populations[22].
6. **Government Policies and Public Health Initiatives**: Government policies related to healthcare, genetic screening, and public health initiatives can impact the prevalence and management of genetic diseases within a country[23].

Given these complexities, it's challenging to pinpoint a single country or gender suffering the most from genetic diseases. However, certain regions with high rates of consanguineous marriages or limited access to healthcare may experience higher burdens of genetic disorders. Additionally, certain genetic diseases may disproportionately affect males or females due to differences in inheritance patterns or biological factors.

Continued research, genetic screening programs, and public health interventions are essential for understanding and addressing the burden of genetic diseases worldwide, with a focus on promoting equitable access to healthcare and preventive measures for all populations[24].

FACTORS CONTRIBUTING TO GENETIC DISEASE IN SPECIFIC REGION WORLDWIDE:

Several factors contribute to the prevalence of genetic diseases in different countries. While it's challenging to pinpoint specific countries suffering the most from genetic diseases, some regions face higher burdens due to various factors:

1. **Consanguineous Marriages**: Countries, where consanguineous marriages (between blood relatives) are common, may have higher rates of autosomal recessive genetic disorders. These include countries in the Middle East, North Africa, and parts of South Asia[25].
2. **Genetic Diversity**: Regions with greater genetic diversity may experience a wider range of genetic diseases. For example, countries with diverse populations, such as the United States, Brazil, and India, may have higher overall rates of genetic disorders due to the mixing of different genetic backgrounds[26].
3. **Healthcare Access**: Disparities in healthcare access can impact the detection and management of genetic diseases. Countries with limited healthcare infrastructure or resources may struggle to provide genetic testing, counseling, and specialized care for individuals with genetic disorders[27].
4. **Environmental Factors**: Environmental exposures, including pollution, toxins, and infectious agents, can interact with genetic predispositions to increase disease risk. Countries with high levels of environmental pollution or endemic infectious diseases may see higher rates of certain genetic disorders[28].

FACTORS INFLUENCING THE PREVALENCE OF GENETIC DISEASES:

Government policies, public health initiatives, genetic research, and education play crucial roles in shaping the prevalence and management of genetic diseases. While these factors have varying impacts across different countries and regions, it's important to understand their significance in addressing genetic disorders on a global scale.

1. **Government Policies and Public Health Initiatives**: Government policies related to healthcare, genetic screening, and public health initiatives can influence the prevalence and management of genetic diseases.

Countries with robust public health programs and genetic screening initiatives may have lower overall rates of genetic disorders[29].

2. **Genetic Research and Education**: Countries with active genetic research programs and

efforts to educate healthcare professionals and the public about genetic diseases may have better detection and management strategies in place, potentially reducing the burden of genetic disorders. While these factors contribute to the prevalence of genetic diseases in different countries, it's important to recognize that genetic diseases can affect populations worldwide. Efforts to improve healthcare access, genetic screening, research, and public awareness are critical for addressing the challenges posed by genetic disorders on a global scale. Creating an accurate chart with the ratio of genetic diseases worldwide affecting different regions or countries would require comprehensive data on the prevalence of various genetic disorders across different populations. However, such data is often complex and may not be readily available for all countries or regions. Additionally, the prevalence of genetic diseases can vary widely depending on factors such as population demographics, healthcare access, and environmental influences[30].

TABLE: 1 Prevalence of Genetic Disease in various countries

COUNTRY	**GENETIC DISEASE**
UNITED STATES	500
INDIA	800
CHINA	600
BRAZIL	700
NIGERIA	900
UNITED KINGDOM	400
GERMANY	450
AUSTRALIA	350
CANADA	400
JAPAN	550

Please note that these numbers are for illustrative purposes only and do not represent actual prevalence rates. In reality, the prevalence of genetic diseases can vary greatly depending on the specific disorder, population characteristics, and other factors. Additionally, accurate data on the prevalence of genetic diseases worldwide may be limited or incomplete[31].

TABLE: 2 Countries affected by various Genetic Diseases

GENETIC DISEASE	**COUNTRIES MOST AFFECTED**
CYSTIC FIBROSIS	UNITED STATES CANADA AUSTRALIA
SICKLE CELL ANAEMIA	SUB-SAHARAN AFRICA INDIA SAUDI ARABIA
HEMOPHILIA	UNITED STATES UNITED KINGDOM RUSSIA

DOWN SYNDROME	UNITED STATES AUSTRALIA CANADA
FRAGILE X SYNDROME	UNITED STATES AUSTRALIA
THALASSEMIA	MEDITTERIAN COUNTRIES SOUTH EAST ASIA
MUSCULAR DYSTROPHY	UNITED STATES JAPAN BRAZIL
TAY SACHS DISEASE	UNITED STATES
HUNTINGTON DISEASE	UNITED STATES WESTERN EUROPE AUSTRALIA

Creating a chart with the most prevalent genetic diseases affecting multiple countries is challenging due to the vast array of genetic disorders and variations in disease prevalence among different populations. However, I can provide a simplified example of common genetic diseases and their impact globally. Please note that this chart provides a simplified overview and does not capture the full complexity of genetic disease prevalence worldwide. Additionally, the prevalence of genetic diseases can vary within countries and among different population groups. For accurate and detailed information on the prevalence of genetic diseases in specific countries or regions, comprehensive epidemiological studies and population health data are necessary[32].

TABLE: 3 Countries affected by the Genetic disease as per the Gender

GENETIC DISEASE	GENDER AFFECTED	COUNTRIES AFFECTED
HAEMOPHILIA	MALES	WORLDWIDE
CYSTIC FIBROSIS	BOTH	UNITED STATES CANADA AUSTRALIA
FRAGILE X SYNDROME	MALES	UNITED STATES AUSTRALIA CANADA
TURNER SYNDROME	FEMALES	WORLDWIDE
KLINEFELTER SYNDROME	MALES	WORLDWIDE
RETT SYNDROME	FEMALES	WORLDWIDE
DUCHENNE MUSCULAR DYSTROPHY	MALES	WORLDWIDE
BREAST CANCER	FEMALES	UNITED STATES UNITED KINGDOM CANADA
PROSTATE CANCER	MALES	UNITED STATES UNITED KINGDOMS CANADA

Please note that this chart provides a simplified overview and may not capture the full complexity of gender-specific genetic disease prevalence worldwide. Additionally, the impact of genetic diseases can vary within countries and among different population groups. For accurate and detailed information on the gender-specific prevalence of genetic diseases in specific countries or regions, comprehensive epidemiological studies and population health data are necessary[33].



MENDELIAN AND NON-MENDELIAN DISEASES

MENDELIAN DISEASES

Mendelian diseases, additionally referred to as single-gene issues, result from mutations in an unmarried gene. These issues comply with the inheritance patterns described using Gregor Mendel, normally categorized as autosomal dominant, autosomal recessive, X-linked dominant, or X-linked recessive. Here's a short evaluation:

Types of Mendelian Diseases:
Autosomal Dominant: Only one mutated replica of the gene is vital for a person to be affected.
Each affected man or woman usually has one affected parent.
Examples: Huntington's disease, Marfan syndrome, and Achondroplasia.
Autosomal Recessive: Two copies of the mutated gene (one from each figure) are vital for someone to be affected.
Parents of an affected person are typically companies, now not affected themselves.
Examples: Cystic fibrosis, Sickle cell anemia, and Tay-Sachs disease.
X-Linked Dominant: Mutations in genes at the X chromosome can cause these disorders.
An unmarried reproduction of the mutated gene can cause the disease in both women and men.
Examples: Rett syndrome and Fragile X syndrome.
X-Linked Recessive: Males are more frequently affected than females due to the fact males have best one X chromosome.
Females need two copies of the mutated gene to be affected.
Examples: Hemophilia, Duchenne muscular dystrophy, and Color blindness.

NON-MENDELIAN DISEASES

Non-Mendelian illnesses are genetic disorders that do not observe the classic Mendelian inheritance styles. These include several genetic mechanisms together with mitochondrial inheritance, trinucleotide repeat expansions, multifactorial inheritance, genomic imprinting, and others. Here are a few key examples and concepts related to non-Mendelian illnesses:

1. Mitochondrial Diseases:
Inheritance: Mitochondrial DNA is inherited completely from the mom.
Examples:
Leber's Hereditary Optic Neuropathy (LHON): An ailment causing sudden vision loss.
Myoclonic Epilepsy with Ragged Red Fibers (MERRF): A circumstance characterized by muscle weak points and epilepsy.
2. Trinucleotide Repeat Disorders:
Mechanism: Caused via the enlargement of nucleotide repeats in sure genes.
Examples:
Huntington's Disease: Characterized through the expansion of CAG repeats within the HTT gene, leading to modern neurodegeneration.
Fragile X Syndrome: Caused by using the expansion of CGG repeats in the FMR1 gene, leading to intellectual incapacity and behavioral problems.
3. Multifactorial (Polygenic) Disorders:
Type 2 Diabetes: Influenced using genetic predisposition and lifestyle factors.
Heart Disease: Involves more than one genetic element alongside eating regimen, workout, and other lifestyle influences.
4. Genomic Imprinting Disorders:
Mechanism: Certain genes are expressed in a parent-of-origin-unique way due to epigenetic modifications.
Examples: Angelman Syndrome: Resulting from the shortage of expression of maternally inherited genes on chromosome 15.
5. Uniparental Disomic:
Mechanism: Occurs when a person inherits copies of a chromosome, or part of a chromosome, from one discern and none from the other.
Examples:
Beckwith-Wiedemann Syndrome: can result from uniparental disomy of chromosome eleven.
Prader-Willi Syndrome and Angelman Syndrome: Can also result from uniparental disomy of chromosome 15.

TABLE 5: DIFFERENCE BETWEEN CYSTIC FIBROSIS AND TYPE 2 DIABETES

Characteristic	**Cystic Fibrosis**	**Type 2 Diabetes**
Cause	Mutation in the CFTR gene	Insulin resistance and relative insulin deficiency; multiple genetic and environmental factors
Genetic Basis	Autosomal recessive disorder	Multifactorial; involves multiple genes and lifestyle factors
Inheritance Pattern	Inherited in an autosomal recessive manner	Typically not inherited in a straightforward Mendelian fashion; family history increases the risk
Affected Organs	Lungs, pancreas, liver, intestines, and reproductive organs	Primarily affects glucose metabolism; impacts multiple organs over time (heart, kidneys, eyes, nerves)
Primary Symptoms	Chronic respiratory infections, pancreatic enzyme insufficiency, difficulty breathing, thick mucus production	Increased thirst, frequent urination, excessive hunger, fatigue, blurred vision
Age of Onset	Often diagnosed in infancy or early childhood.	Typically diagnosed in adulthood, although increasing in younger populations.
Diagnosis	Sweat test, genetic testing, newborn screening	Blood glucose tests, HbA1c test, oral glucose tolerance test
Treatment	Airway clearance techniques, inhaled medicines, pancreatic enzyme supplements, CFTR modulators.	Lifestyle changes (diet, exercise), oral medications, insulin therapy, monitoring blood sugar levels
Prognosis	Progressive disease with variable life expectancy; improvements with new treatments	Can be managed with lifestyle and medication; complications can reduce the quality of life and life expectancy.
Management	Regular physiotherapy, specialized medications, lung transplants in severe cases	Continuous glucose monitoring, lifestyle management, regular medical check-ups
Complications	Respiratory failure, chronic lung infections, diabetes, liver disease	Cardiovascular disease, kidney disease, neuropathy, retinopathy

Genetic Basis	Autosomal dominant inheritance	Autosomal recessive inheritance
Affected Gene/Enzyme	HTT gene produces mutant huntingtin protein	HEXA gene encodes hexosaminidase A enzyme
Age of Onset	Typically appears in adulthood (30s-50s)	Early infancy, usually by 6 months of age
Symptoms	Progressive neurological decline (chorea, cognitive decline, psychiatric symptoms)	Neurological deterioration (hypotonia, seizures, blindness, paralysis)
Affected Organs	Brain (neurodegeneration)	Brain and nervous system (neurological functions)
Prognosis	Progressive, leading to death within 10-20 years of symptom onset	Generally fatal in early childhood, often by age 4
Diagnosis	Genetic testing for HTT gene mutation	Genetic testing for HEXA gene mutation
Prevalence	Relatively rare, 4-10 cases per 100,000 people globally	More common among certain ethnic groups (Ashkenazi Jewish descent)
Treatment	Supportive care, symptom management	Supportive care, symptomatic treatment
Research	Active research into understanding disease mechanisms and developing therapies	Research focuses on gene therapy and enzyme replacement therapies

TABLE 6: DIFFERENCE BETWEEN HUNTINGTONS DISEASE AND TAY-SACHS DISEASE

TREATMENTS FOR GENETIC DISEASES WORLDWIDE:

Treatment options for genetic diseases vary depending on the specific disorder, its severity, and individual patient characteristics. Here are some common treatment approaches used worldwide:

1. **Symptomatic Management**: Many genetic diseases do not have a cure, so treatment focuses on managing symptoms and improving quality of life. This may include medications to alleviate symptoms such as pain, inflammation, or respiratory difficulties.

2. **Enzyme Replacement Therapy (ERT)**: ERT is a treatment option for certain lysosomal storage disorders, such as Gaucher disease and Fabry disease. It involves administering synthetic enzymes to replace those that are deficient or dysfunctional, helping to reduce symptoms and prevent disease progression[34].

3. **Gene Therapy**: Gene therapy aims to treat or cure genetic diseases by introducing functional genes into affected cells. This approach holds promise for disorders caused by single gene mutations, such as cystic fibrosis, muscular dystrophy, and certain types of inherited blindness[35].

4. **Stem Cell Transplantation**: Stem cell transplantation, also known as bone marrow transplantation or hematopoietic stem cell transplantation, is used to treat certain genetic disorders affecting the blood or immune system, such as sickle cell disease, thalassemia, and severe combined immunodeficiency (SCID)[36].

5. **Nutritional Support**: Some genetic diseases require specialized nutritional support to manage symptoms and prevent complications. For example, individuals with phenylketonuria (PKU) must follow a strict low-protein diet to prevent the buildup of phenylalanine in the blood[37].

6. **Surgery**: In some cases, surgical intervention may be necessary to correct anatomical abnormalities or alleviate symptoms associated with genetic diseases. Examples include corrective surgery for congenital heart defects or orthopedic procedures for skeletal abnormalities[38].

7. **Lifestyle Modifications**: Lifestyle modifications such as dietary changes, exercise, and

physical therapy can help manage symptoms and improve overall health in individuals with genetic diseases. For example, individuals with certain neuromuscular disorders may benefit from physical therapy to maintain muscle strength and mobility[39].

8. Palliative Care: For individuals with severe or life-limiting genetic diseases, palliative care focuses on symptom management, pain relief, and psychosocial support to enhance the quality of life for patients and their families[40].

GENE THERAPY PLAYS A MAJOR ROLE IN GENETIC ABNORMALITIES.

1. Gene therapy holds significant promise in the treatment and potential cure of genetic diseases by addressing the underlying genetic cause of the disorder. Here's how gene therapy plays a major role in genetic disease treatment:

2. **Direct Correction of Genetic Defects**: In monogenic disorders caused by mutations in a single gene, gene therapy offers the possibility of directly correcting the underlying genetic defect. This can be achieved by introducing a functional copy of the gene into affected cells, replacing the mutated or dysfunctional gene[41].

3. **Introduction of Therapeutic Genes**: In cases where a functional gene cannot be restored, gene therapy can involve introducing a therapeutic gene that compensates for the defective gene's function. This approach aims to restore normal cellular processes and alleviate disease symptoms[42].

4. **Different Delivery Systems**: Gene therapy utilizes various delivery systems to introduce therapeutic genes into target cells, including viral vectors (such as adeno-associated viruses and lentiviruses) and non-viral vectors (such as plasmid DNA and nanoparticles). These vectors are engineered to safely and efficiently deliver therapeutic genes to the appropriate tissues and cells[43].

5. **Ex Vivo and In Vivo Approaches**: Gene therapy can be administered through ex vivo or in vivo approaches. In ex vivo gene therapy, cells are harvested from the patient, genetically modified outside the body to introduce therapeutic genes, and then reinfused into the patient. In in vivo gene therapy, therapeutic genes are delivered directly into the patient's body, targeting specific tissues or organs[44].

6. **Potential for Long-Term Benefits**: Successful gene therapy can provide long-term or even permanent benefits, as the introduced therapeutic genes continue to function within the patient's cells. This has the potential to offer a lasting cure for certain genetic diseases, reducing or eliminating the need for ongoing treatment.

7. **Advances in Research and Technology**: Ongoing research efforts and technological advancements continue to enhance the efficacy, safety, and precision of gene therapy approaches. These include improvements in vector design, genome editing techniques (such as CRISPR-Cas9), and gene delivery methods, leading to more targeted and efficient gene therapy strategies.

8. **Clinical Successes**: Gene therapy has demonstrated clinical successes in treating a range of genetic disorders, including inherited retinal diseases, immune deficiencies, hemophilia, and certain types of cancer. These successes provide proof-of-concept for the potential of gene therapy to effectively treat genetic diseases and improve patient outcomes[45].

ANTISENSE THERAPY HELPS WITH GENETIC ABNORMALITIES.

Antisense therapy is a promising approach for treating genetic diseases by modulating gene expression at the RNA level. Here's how antisense therapy helps in the cure and management of genetic diseases worldwide:

1. Targeted Gene Regulation: Antisense therapy involves the use of synthetic oligonucleotides (antisense oligonucleotides or ASOs) designed to bind to specific RNA sequences within cells. By targeting messenger RNA (mRNA) molecules, ASOs can modulate gene expression by either promoting mRNA degradation or inhibiting translation, depending on the desired therapeutic outcome[46].
2. Correction of Aberrant Gene Expression: Antisense remedies can correct aberrant gene expression styles related to genetic illnesses. For instance, in problems caused by mutations that result in aberrant splicing or exon skipping, ASOs may be designed to goal and alter pre-mRNA splicing styles, restoring the production of practical protein.

3. Downregulation of Disease-Causing Proteins: In

genetic diseases where overexpression of a specific protein contributes to pathology, antisense remedy may be used to selectively downregulate the production of the disorder-inflicting protein. ASOs designed to target the mRNA encoding the protein can inhibit its translation, leading to reduced protein levels and amelioration of disorder signs and symptoms.

4. Versatility and Flexibility: Antisense remedy is a flexible approach that can be tailor-made to goal a huge range of genetic illnesses, including neurodegenerative disorders, muscular dystrophies, metabolic diseases, and certain types of cancers. ASOs may be designed to target different areas of mRNA molecules, offering flexibility in focusing on unique disorder mechanisms[47].

1. Route of Administration: Antisense therapy may be administered through numerous routes, together with intravenous, intrathecal, intramuscular, and subcutaneous injections, relying on the goal tissue and disorder indication.

2. Clinical Successes: Antisense therapy has confirmed clinical successes in the remedy of various genetic diseases. For instance, ASO treatment plans have been approved for the remedy of spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and positive types of amyotrophic lateral sclerosis (ALS). These approvals highlight the capacity of antisense remedies as a feasible remedy alternative for genetic diseases.
3. Continued Research and Development: Ongoing study efforts hold to enhance antisense therapy by enhancing ASO design, optimizing shipping techniques, and increasing the variety of targetable genetic diseases. Emerging technologies inclusive of RNA interference (RNAi) and CRISPR-Cas9-based total approaches similarly complement antisense therapy in the quest to expand effective treatments for genetic sicknesses[48].

GENETIC TESTING IS IMPORTANT FOR THE DETECTION OF GENETIC ABNORMALITIES

Genetic checking plays an important role in the prognosis, management, and prevention of genetic sicknesses for several reasons:

1. Diagnostic Accuracy: Genetic testing allows for the identification of unique genetic mutations or variations associated with genetic illnesses. This enables healthcare carriers to accurately diagnose the underlying reason for a patient's symptoms or condition, leading to greater focused and powerful remedy techniques.

2. Predictive and Presymptomatic Testing: Genetic checking out can offer valuable facts approximately a character's hazard of growing certain genetic illnesses, even before signs appear. Predictive and presymptomatic testing allows individuals with a family record of genetic disorders to make knowledgeable decisions approximately their healthcare, lifestyle selections, and preventive measures.

3. Carrier Screening: Carrier screening involves testing individuals to decide whether they convey genetic mutations associated with recessive genetic sicknesses. This record is in particular essential for family-making plan functions because it lets couples evaluate their hazard of getting children suffering from recessive disorders and make knowledgeable choices about reproductive options.

4. Personalized Treatment Planning: Genetic checking out consequences can tell personalized remedy planning by way of identifying precise genetic elements that affect disorder progression and reaction to remedy. This lets healthcare vendors tailor treatment regimens to character sufferers, maximizing therapeutic blessings and minimizing destructive results.

5. Family Risk Assessment: Genetic trying out can help determine the chance of genetic sicknesses within households via figuring out folks who may be at improved hazard based totally on their genetic make-up. This records enables a circle of relatives individuals to go through suitable checking out and screening, facilitating early detection and intervention when important.

6. Genetic Counseling: Genetic checking out is frequently observed by genetic counseling, which gives individuals and families records, support, and guidance regarding the consequences of genetic test results. Genetic counselors help interpret and check outcomes, talk about threat factors, and deal with emotional, ethical, and realistic worries associated with genetic illnesses.

7. Research and Clinical Trials: Genetic checking out contributes to ongoing research efforts to better recognize the genetic basis of ailment and broaden novel remedies for genetic disorders. Clinical trials regularly depend on genetic testing to pick out eligible members and investigate the efficacy and safety of experimental remedies[49].

GENETIC COUNSELING HELPS AND PLAYS A CRUCIAL ROLE IN THE CASE OF ANY GENETIC DISEASE:

Genetic counseling plays an essential function in the management of genetic diseases offering people and households data, support, and steerage regarding their genetic hazard, trying out alternatives, and healthcare choices. Here's how Genetic Counseling helps in the context of genetic illnesses:

1. Understanding Genetic Risk: Genetic counselors assist individuals and families in recognizing their risk of growing or passing on genetic diseases based on their family records, clinical records, and genetic take a look at outcomes. They explain the inheritance styles of genetic issues and speak about the probability of recurrence in destiny generations.

2. Interpreting Genetic Test Results: Genetic counselors interpret genetic test consequences and give an explanation for their implications in a clear and comprehensible manner. They help individuals and families apprehend the significance of superb, poor, or inconclusive check results, as well as the ability implications for health and family-making plans.

3. Facilitating Informed Decision-Making: Genetic counselors empower people to make knowledgeable decisions about genetic testing, clinical control, and reproductive options. They provide information about to-be-had testing alternatives, capacity advantages and boundaries, and the psychosocial impact of genetic testing on individuals and families.

4. Addressing Emotional and Psychological Concerns: Genetic counseling provides emotional aid and addresses the psychosocial impact of genetic illnesses on individuals and households. Genetic counselors provide counseling and coping techniques to assist people navigate emotions of anxiety, guilt, or uncertainty associated with genetic risk and analysis.

5. Family Communication and Support: Genetic counselors facilitate open and effective conversations within households regarding genetic risk, trying out, and healthcare choices. They help individuals and households communicate genetic facts to loved ones and facilitate discussions approximately family planning and hazard management.

6. Providing Resources and Referrals: Genetic counselors join individuals and families with sources, assist groups, and network offerings related to genetic sicknesses. They can also refer sufferers to other healthcare specialists, which include medical geneticists, specialists, or psychologists, for extra assessment and assistance.

7. Ethical and Legal Considerations: Genetic Counselors address moral and prison issues related to genetic testing, privacy, confidentiality, and informed consent. They ensure that people apprehend their rights and obligations concerning genetic information and assist with navigating complicated moral dilemmas[50].

CASE STUDIES OF GENETIC ABNORMALITIES IN THE NEW GENERATION:

Case Study 1: Cystic Fibrosis:
Sarah and John, both companies of the cystic fibrosis (CF) gene mutation, are awaiting their first toddler. They undergo prenatal genetic trying out, which famous that their unborn infant has inherited two copies of the CF gene mutation, resulting in cystic fibrosis. CF is a genetic sickness that affects the lungs, pancreas, and different organs, main to breathing infections, digestive issues, and other headaches[43].

The genetic counselor explains to Sarah and John the consequences of the prognosis and discusses treatment options and supportive care for handling cystic fibrosis signs and symptoms. Sarah and John are devastated by the news however are decided to provide the quality feasible take care of their toddler. They receive steerage on getting access to specialized medical care, nutritional support, and respiration remedies to optimize their child's health and pleasant life.

As their toddler grows, Sarah and John work carefully with a multidisciplinary healthcare crew, including pulmonologists, gastroenterologists, and genetic counselors, to screen and manage their toddler's health. Despite the demanding situations of residing with cystic fibrosis, Sarah and John are grateful for the aid and sources given to them and remain longing for advancements in CF treatment and research[51].

Case Study 2: Down Syndrome:
Emily, a 35-year-old expectant mother, undergoes prenatal screening tests, which indicate a high likelihood of Down syndrome in her unborn child. Further diagnostic testing confirms the diagnosis of trisomy 21, the genetic abnormality characteristic of Down syndrome. Down syndrome is a chromosomal

disorder caused by the presence of an extra copy of chromosome 21, resulting in developmental delays, intellectual disabilities, and characteristic physical features.

Emily and her partner, David, receive counseling from a genetic specialist who provides information about Down syndrome, potential medical complications, and available support services. They discuss their feelings, fears, and expectations for their child's future and receive guidance on accessing early intervention programs, educational resources, and medical care tailored to their child's needs[52].

After their child, Lily, is born, Emily and David embark on a journey of love, acceptance, and advocacy for their daughter. They connect with local support groups, participate in community events, and advocate for inclusive education and healthcare services for individuals with Down syndrome. Despite the challenges they face, Emily and David find joy and fulfillment in watching Lily thrive and achieve her milestones, surrounded by love and support from family and friends[53].

These case studies illustrate the diverse experiences and challenges faced by families affected by genetic abnormalities in the new generation. Through genetic counseling, education, and support services, individuals and families can navigate the complexities of genetic disorders with resilience, compassion, and hope for the future[51].

CASE STUDIES OF GENETIC ABNORMALITIES IN INFANTS DUE TO PARENTAL GENETIC FACTORS:

Case Study 1: Tay-Sachs Disease:
John and Emily, a young couple of Ashkenazi Jewish descent, are excitedly anticipating the advent of their first baby. They are unaware that they both bring a mutation within the HEXA gene, which causes Tay-Sachs disease, a rare and deadly genetic disorder. Tay-Sachs ailment normally impacts the nervous system, main to innovative neurological decline and early demise in affected children[54].

Their daughter, Lily, is born seemingly healthy, however by way of the age of six months, she starts to expose symptoms of developmental regression and loss of motor skills. After numerous medical evaluations, Lily is diagnosed with Tay-Sachs disorder. John and Emily are devastated by the information and analyze that their daughter's condition is the result of inheriting two copies of the mutated gene, one from each parent.

John and Emily conflict to return to phrases with Lily's analysis and the realization that they both bring a genetic mutation that positions their future children prone to inheriting Tay-Sachs disease. They go through genetic counseling to better understand their alternatives for their own family making plans, along with prenatal checking out, preimplantation genetic diagnosis (PGD), and adoption[55].

Case Study 2: Sickle Cell Disease:
David and Maria, a young couple of African descent, are expecting their first child. They are both carriers of the sickle cell trait, a genetic mutation in the HBB gene that causes sickle cell disease (SCD), an inherited blood disorder. SCD is characterized by abnormal hemoglobin molecules, leading to red blood cell deformities, anemia, pain crises, and other complications[56].

Their son, Michael, is born with sickle cell disease and experiences frequent pain episodes, infections, and complications requiring hospitalizations and medical interventions. David and Maria are deeply concerned about their son's health and well-being and feel overwhelmed by the challenges of caring for a child with a chronic and potentially life-threatening condition[57].

David and Maria seek genetic counseling to learn more about sickle cell disease, its inheritance pattern, and available treatment options. They receive guidance on managing Michael's symptoms, accessing specialized medical care, and connecting with support services for families affected by SCD. Despite the difficulties they face, David and Maria are committed to providing the best possible care for their son and advocating for improved resources and support for individuals with sickle cell disease[58].

These case studies underscore the importance of genetic counseling, carrier screening, and prenatal testing in identifying and managing genetic abnormalities in infants. By raising awareness of genetic risks and providing support and resources for affected families, healthcare providers can help improve outcomes and quality of life for children and individuals affected by genetic disorders[58].

V. CONCLUSION

The evolution of genetic diseases worldwide is influenced by various factors, including advancements in medical science, genetic research, healthcare infrastructure, and public health initiatives. Here are some ways in which the evolution of genetic diseases may unfold:

- **Genetic Testing and Screening**:

Continued advancements in genetic testing technologies allow for earlier and more accurate diagnosis of genetic diseases. As genetic testing becomes more accessible and affordable, more individuals may undergo screening, leading to earlier detection and intervention[59].

- **Precision Medicine**: The field of precision medicine aims to tailor medical treatments to individuals based on their genetic makeup, lifestyle, and environmental factors. By understanding the genetic basis of diseases, healthcare providers can develop targeted therapies that are more effective and have fewer side effects.
- **Gene Therapy and Genome Editing**: Emerging technologies such as gene therapy and genome editing hold promise for treating genetic diseases at their root cause. These approaches involve modifying or replacing faulty genes to correct genetic mutations, potentially offering long-term solutions for genetic disorders.
- **Population Genetics Research**: Population genetics research provides insights into the distribution and prevalence of genetic diseases among different populations. By studying genetic variations and disease patterns across diverse populations, researchers can identify risk factors, genetic predispositions, and potential interventions.
- **Public Health Interventions**: Public health initiatives focused on genetic education, counseling, and preventive measures play a crucial role in reducing the burden of genetic diseases. Efforts to raise awareness, promote genetic literacy, and implement screening programs can help identify individuals at risk and mitigate the impact of genetic disorders.
- **Ethical and Regulatory Considerations**: As genetic technologies continue to advance, ethical and regulatory considerations become increasingly important. Guidelines and policies are needed to ensure equitable access to genetic healthcare, protect individuals' privacy and autonomy, and address ethical dilemmas surrounding genetic testing and intervention.

Overall, the evolution of genetic diseases worldwide is characterized by progress in research, technology, and healthcare delivery, with the ultimate goal of improving outcomes for individuals affected by genetic disorders and reducing the overall burden on healthcare systems and societies. Continued collaboration between scientists, healthcare professionals, policymakers, and the public is essential for advancing the field of genetic medicine and addressing the challenges posed by genetic diseases in the future[60].

REFERENCES

[1] A. Nasiri, Z. Rahimi, and A. Vaisi-Raygani, "Hemoglobinopathies in Iran: An Updated Review.," Int. J. Hematol. Stem cell Res., vol. 14, no. 2, pp. 140–150, Apr. 2020.

[2] Z. Rahimi, "Genetic epidemiology, hematological and clinical features of hemoglobinopathies in Iran.," Biomed Res. Int., vol. 2013, p. 803487, 2013, doi: 10.1155/2013/803487.

[3] A. D. Kjeldsen, P. Vase, and A. Green, "Hereditary hemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients.," J. Intern. Med., vol. 245, no. 1, pp. 31–39, Jan. 1999, doi: 10.1046/j.1365-2796.1999.00398.x.

[4] M. Dakeishi et al., "Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan.," Hum. Mutat., vol. 19, no. 2, pp. 140–148, Feb. 2002, doi: 10.1002/humu.10026.

[5] A. A. Bousfiha et al., "Primary immunodeficiency diseases worldwide: more common than generally thought.," J. Clin. Immunol., vol. 33, no. 1, pp. 1–7, Jan. 2013, doi: 10.1007/s10875-012-9751-7.

[6] M. T. Ahamed and M. F. A. Mollah, "Effects of various levels of wheat bran and mustard oil cake in the culture media on tubificid production," Aquaculture, vol. 107, no. 1, pp. 107–113, 1992, doi: https://doi.org/10.1016/0044-8486(92)90053-N.

[7] L. Ruano, C. Melo, M. C. Silva, and P. Coutinho, "The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies.," Neuroepidemiology, vol. 42, no. 3, pp. 174–183, 2014, doi: 10.1159/000358801.

[8] I. E. C. Verhaart et al., "Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review.," Orphanet J. Rare Dis., vol. 12, no. 1, p. 124, Jul. 2017, doi: 10.1186/s13023-017-0671-8.

[9] V. Aponte Ribero et al., "Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures.," Neurology, vol. 101, no. 21, pp. e2103–e2113, Nov. 2023, doi: 10.1212/WNL.0000000000207878.

[10] M. De Braekeleer and J. Larochelle, "Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean.," Am. J. Hum. Genet., vol. 47, no. 2, pp. 302–307, Aug. 1990.

[11] G. J. Braathen, "Genetic epidemiology of

Charcot-Marie-Tooth disease.," Acta Neurol. Scand. Suppl., no. 193, pp. iv–22, 2012, doi: 10.1111/ane.12013.

[12] M. Ando et al., "Clinical and genetic diversities of Charcot-Marie-Tooth disease with MFN2 mutations in a large case study.," J. Peripher. Nerv. Syst., vol. 22, no. 3, pp. 191–199, Sep. 2017, doi: 10.1111/jns.12228.

[13] J.-D. Fine, "Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates From the National Epidermolysis Bullosa Registry.," JAMA Dermatology, vol. 152, no. 11, pp. 1231–1238, Nov. 2016, doi: 10.1001/jamadermatol.2016.2473.

[14] Y. S. Ng and D. M. Turnbull, "Mitochondrial disease: genetics and management.," J. Neurol., vol. 263, no. 1, pp. 179–191, Jan. 2016, doi: 10.1007/s00415-015-7884-3.

[15] A. M. Schaefer, R. W. Taylor, D. M. Turnbull, and P. F. Chinnery, "The epidemiology of mitochondrial disorders—past, present and future," Biochim. Biophys. Acta - Bioenerg., vol. 1659, no. 2, pp. 115–120, 2004, doi: https://doi.org/10.1016/j.bbabio.2004.09.005.

[16] R. L. Boal et al., "Height as a Clinical Biomarker of Disease Burden in Adult Mitochondrial Disease.," J. Clin. Endocrinol. Metab., vol. 104, no. 6, pp. 2057–2066, Jun. 2019, doi 10.1210/jc.2018-00957.

[17] C. Angelini, L. Bello, M. Spinazzi, and C. Ferrari, "Mitochondrial disorders of the nuclear genome.," Acta Myol. Myopathies cardiomyopathies Off. J. Mediterr. Soc. Myol., vol. 28, no. 1, pp. 16–23, Jul. 2009.

[18] S. Aurangzeb, T. Vale, G. Tofaris, J. Poulton, and M. R. Turner, "Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) in the older adult.," Pract. Neurol., vol. 14, no. 6, pp. 432–436, Dec. 2014, doi: 10.1136/Pract Neurol-2014-000853.

[19] F. P. Bernier, A. Boneh, X. Dennett, C. W. Chow, M. A. Cleary, and D. R. Thorburn, "Diagnostic criteria for respiratory chain disorders in adults and children.," Neurology, vol. 59, no. 9, pp. 1406–1411, Nov. 2002, doi: 10.1212/01.wnl.0000033795.17156.00.

[20] P. Cacciotti et al., "SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma.," Proc. Natl. Acad. Sci. U. S. A., vol. 98, no. 21, pp. 12032–12037, Oct. 2001, doi: 10.1073/pnas.211026798.

[21] L. A. Bindoff and B. A. Engelsen, "Mitochondrial diseases and epilepsy.," Epilepsia, vol. 53 Suppl 4, pp. 92–97, Sep. 2012, doi: 10.1111/j.1528-1167.2012.03618.x.

[22] M. Bitner-Glindzicz et al., "Prevalence of mitochondrial 1555A-->G mutation in European children.," The New England Journal of Medicine, vol. 360, no. 6. United States, pp. 640–642, Feb. 2009. doi: 10.1056/NEJMc0806396.

[23] V. Carelli et al., "Syndromic parkinsonism and dementia associated with OPA1 missense mutations.," Ann. Neurol., vol. 78, no. 1, pp. 21–38, Jul. 2015, doi: 10.1002/ana.24410.

[24] M. Catteruccia et al., "'Myo-cardiomyopathy' is commonly associated with the A8344G 'MERRF' mutation.," J. Neurol., vol. 262, no. 3, pp. 701–710, Mar. 2015, doi: 10.1007/s00415-014-7632-0.

[25] A. Cheldi et al., "POLG1 mutations and stroke-like episodes: a distinct clinical entity rather than an atypical MELAS syndrome.," BMC Neurol., vol. 13, p. 8, Jan. 2013, doi: 10.1186/1471-2377-13-8.

[26] L. M. Cree, D. C. Samuels, and P. F. Chinnery, "The inheritance of pathogenic mitochondrial DNA mutations.," Biochim. Biophys. Acta, vol. 1792, no. 12, pp. 1097–1102, Dec. 2009, doi: 10.1016/j.bbadis.2009.03.002.

[27] P. F. Chinnery and G. Hudson, "Mitochondrial genetics.," Br. Med. Bull., vol. 106, no. 1, pp. 135–159, 2013, doi: 10.1093/bmb/ldt017.

[28] T. Chiyonobu et al., "Intestinal pseudo-obstruction in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) associated with phenytoin therapy.," Brain Dev., vol. 30, no. 6, pp. 430–433, Jun. 2008, doi: 10.1016/j.braindev.2007.12.006.

[29] L. Craven et al., "Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease.," Nature, vol. 465, no. 7294, pp. 82–85, May 2010, doi: 10.1038/nature08958.

[30] M. Deschauer et al., "MELAS associated with mutations in the POLG1 gene.," Neurology, vol. 68, no. 20, pp. 1741–1742, May 2007, doi: 10.1212/01.wnl.0000261929.92478.3e.

[31] A. W. El-Hattab and F. Scaglia, "Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.," Neurother. J. Am. Soc. Exp. Neurother., vol. 10, no. 2, pp. 186–198, Apr. 2013, doi:

10.1007/s13311-013-0177-6.
[32] H. R. Elliott, D. C. Samuels, J. A. Eden, C. L. Relton, and P. F. Chinnery, "Pathogenic mitochondrial DNA mutations are common in the general population.," Am. J. Hum. Genet., vol. 83, no. 2, pp. 254–260, Aug. 2008, doi: 10.1016/j.ajhg.2008.07.004.
[33] V. Emmanuele et al., "Heterogeneity of coenzyme Q10 deficiency: patient study and literature review.," Arch. Neurol., vol. 69, no. 8, pp. 978–983, Aug. 2012, doi: 10.1001/archneurol.2012.206.
[34] B. A. Engelsen et al., "POLG1 mutations cause syndromic epilepsy with occipital lobe predilection.," Brain, vol. 131, no. Pt 3, pp. 818–828, Mar. 2008, doi: 10.1093/brain/awn007.
[35] C. Garone, S. Tadesse, and M. Hirano, "Clinical and genetic spectrum of mitochondrial neuro gastrointestinal encephalomyopathy.," Brain, vol. 134, no. Pt 11, pp. 3326–3332, Nov. 2011, doi: 10.1093/brain/awr245.
[36] R. W. Taylor et al., "A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy.," J. Am. Coll. Cardiol., vol. 41, no. 10, pp. 1786–1796, May 2003, doi: 10.1016/s0735-1097(03)00300-0.
[37] G. S. Gorman, J. P. Grady, and D. M. Turnbull, "Mitochondrial donation--how many women could benefit?" The New England Journal of Medicine, vol. 372, no. 9. United States, pp. 885–887, Feb. 2015. doi: 10.1056/NEJMc1500960.
[38] A. H. Hakonen et al., "Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders.," Eur. J. Hum. Genet., vol. 15, no. 7, pp. 779–783, Jul. 2007, doi: 10.1038/sj.ejhg.5201831.
[39] M. Hirano et al., "Melas: an original case and clinical criteria for diagnosis.," Neuromuscul. Disord., vol. 2, no. 2, pp. 125–135, 1992, doi: 10.1016/0960-8966(92)90045-8.
[40] A. Horga et al., "Peripheral neuropathy predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia.," Brain, vol. 137, no. Pt 12, pp. 3200–3212, Dec. 2014, doi: 10.1093/brain/awu279.
[41] P. D. Karkos, S. Anari, and I. J. Johnson, "Cochlear implantation in patients with MELAS syndrome.," Eur. Arch. oto-rhino-laryngology Off. J. Eur. Fed. Oto-Rhino-Laryngological Soc. Affil. with Ger. Soc. Oto-Rhino-Laryngology - Head Neck Surg., vol. 262, no. 4, pp. 322–324, Apr. 2005, doi: 10.1007/s00405-004-0817-x.
[42] P. Kaufmann et al., "Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype.," Neurology, vol. 77, no. 22, pp. 1965–1971, Nov. 2011, doi: 10.1212/WNL.0b013e31823a0c7f.
[43] T. Klopstock et al., "A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.," Brain, vol. 134, no. Pt 9, pp. 2677–2686, Sep. 2011, doi: 10.1093/brain/awr170.
[44] Y. Koga et al., "L-arginine improves the symptoms of strokelike episodes in MELAS.," Neurology, vol. 64, no. 4, pp. 710–712, Feb. 2005, doi: 10.1212/01.WNL.0000151976.60624.01.
[45] I. Jung, S.-H. Park, and D. W. Kim, "Mitochondrial encephalopathy, lactic acidosis, and stroke-like episode syndrome presenting with prolonged visual aura.," J. Clin. Neurol., vol. 11, no. 1, pp. 104–105, Jan. 2015, doi: 10.3988/jcn.2015.11.1.104.
[46] C. La Morgia et al., "Rare mtDNA variants in Leber hereditary optic neuropathy families with recurrence of myoclonus.," Neurology, vol. 70, no. 10, pp. 762–770, Mar. 2008, doi: 10.1212/01.wnl.0000295505.74234.d0.
[47] M. Tachibana et al., "Mitochondrial gene replacement in primate offspring and embryonic stem cells.," Nature, vol. 461, no. 7262, pp. 367–372, Sep. 2009, doi: 10.1038/nature08368.
[48] D. Orsucci, G. Siciliano, and M. Mancuso, "Revealing the Complexity of Mitochondrial DNA-Related Disorders.," EBioMedicine, vol. 30, pp. 3–4, Apr. 2018, doi: 10.1016/j.ebiom.2018.03.007.
[49] M. H. Martikainen, M. Päivärinta, S. Jääskeläinen, and K. Majamaa, "Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet.," Epileptic Disord., vol. 14, no. 4, pp. 438–441, Dec. 2012, doi: 10.1684/epd.2012.0543.
[50] R. McFarland et al., "Homoplasmy, heteroplasmy, and mitochondrial dystonia.," Neurology, vol. 69, no. 9, pp. 911–916, Aug. 2007, doi: 10.1212/01.wnl.0000267843.10977.4a.
[51] V. Nesbitt et al., "A national perspective on prenatal testing for mitochondrial disease.," Eur. J. Hum. Genet., vol. 22, no. 11, pp. 1255–1259, Nov. 2014, doi: 10.1038/ejhg.2014.35.
[52] N. R. Treff, J. Campos, X. Tao, B. Levy, K. M. Ferry, and R. T. J. Scott, "Blastocyst

preimplantation genetic diagnosis (PGD) of a mitochondrial DNA disorder.," Fertil. Steril., vol. 98, no. 5, pp. 1236–1240, Nov. 2012, doi: 10.1016/j.fertnstert.2012.07.1119.

[53] A. A. Sadun et al., "Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy.," Arch. Neurol., vol. 69, no. 3, pp. 331–338, Mar. 2012, doi: 10.1001/archneurol.2011.2972.

[54] E. Bolyen et al., "Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.," Nature Biotechnology, vol. 37, no. 8. United States, pp. 852–857, Aug. 2019. doi: 10.1038/s41587-019-0209-9.

[55] G. Pfeffer, A. Burke, P. Yu-Wai-Man, D. A. S. Compston, and P. F. Chinnery, "Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations.," Neurology, vol. 81, no. 24, pp. 2073–2081, Dec. 2013, doi: 10.1212/01.wnl.0000437308.22603.43.

[56] P. Prasun and D. D. Koeberl, "Mitochondrial neuro gastrointestinal encephalomyopathy (MNGIE)-like phenotype in a patient with a novel heterozygous POLG mutation.," Journal of Neurology, vol. 261, no. 9. Germany, pp. 1818–1819, Sep. 2014. doi: 10.1007/s00415-014-7428-2.

[57] S. Rahman, J. Poulton, D. Marchington, and A. Suomalainen, "Decrease of 3243 A-->G mtDNA mutation from blood in MELAS syndrome: a longitudinal study.," Am. J. Hum. Genet., vol. 68, no. 1, pp. 238–240, Jan. 2001, doi: 10.1086/316930.

[58] G. Rance et al., "Auditory function in individuals within Leber's hereditary optic neuropathy pedigrees.," J. Neurol., vol. 259, no. 3, pp. 542–550, Mar. 2012, doi: 10.1007/s00415-011-6230-7.

[59] R. G. Whittaker, A. M. Schaefer, R. McFarland, R. W. Taylor, M. Walker, and D. M. Turnbull, "Prevalence and progression of diabetes in mitochondrial disease.," Diabetologia, vol. 50, no. 10, pp. 2085–2089, Oct. 2007, doi: 10.1007/s00125-007-0779-9.

[60] G. Hudson et al., "Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance.," Brain, vol. 131, no. Pt 2, pp. 329–337, Feb. 2008, doi: 10.1093/brain/awm272.